Compare ADMA Biologics Inc (ADMA) vs FedEx Corporation (FDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs FedEx Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while FedEx Corporation trades at $308.82 (market cap $74.66B). The key difference: FedEx Corporation is far larger — about 35.1× ADMA Biologics Inc's market cap, and FedEx Corporation pays a 1.56% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FDX | |
|---|---|---|
Market Cap | $2.13B | $74.66B |
Sector | Health | Industrials |
52-Week High | $20.38 | $338.75 |
52-Week Low | $7.60 | $174.81 |
Enterprise Value | $2.20B | $108.67B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
FedEx trades at $312.88, down slightly by 0.04% on the day, with a bearish technical signal from moving averages. Recent quarterly earnings have consistently beaten expectations, including Q1 2026 EPS of $6.31 versus $5.91 expected. The company is streamlining operations, highlighted by the sale of its supply chain unit to CMA CGM for $1.4 billion, while maintaining solid cash flow from operations of $7.04 billion in 2025.
The outlook is mixed: analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain. Key risks include soft shipping demand and ongoing cost pressures. Upside potential hinges on successful execution of efficiency initiatives like DRIVE and Network 2.0 to expand profitability beyond current 4.88% net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
